The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin.

The study is seeking participants who:

* Are aged 12 years or older.
* Were confirmed to have atopic dermatitis (AD) at least 12 months ago.
* Are not having an effective treatment result from medicines that are applied on skin for AD.
* Are considered by their doctors to have moderate to severe AD.

The study treatment period will be 52 weeks. During the 24-week initial treatment period, participants will be randomized to one of three study treatments - tilrekimig, dupilumab, or placebo. Placebo does not have any medicine in it but looks just like the medicine being studied. These treatments will be randomized based on a 2:2:1 ratio. This means out of 1375 participants, about 550 participants will receive tilrekimig, 550 will receive dupilumab, and 275 will receive placebo. This will be followed by a 28-week maintenance period. The last dose of study treatment will be administered at week 48.

Some participants will join the long-term extension (LTE) study C4531008 at week 52. A long-term extension study is an additional study that some participants may be able to join after completing the study if they are interested and meet eligibility requirements. It allows researchers to continue collecting information about how well the study medicine works. It also helps them assess how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last dose of study treatment.

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

Marietta, GA

Arlington, VA

Indianapolis, IN

Camp Hill, PA

Sugar Land

Troy, MI

Huntington Beach, CA

Boise, ID

Northridge, CA

Pfizer

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Winter Park, FL

NMC Research

Boca Raton, FL

Margate, FL

Elias Dermatology - Fort Lauderdale, FL

North Miami Beach, FL

Charlotte, NC

Wendy Daigle, Director of Clinical Operations

Southshore, Metairie, LA

Norfolk Office

Plainfield, IN

Woodbury, NY

Northville, MI

Auburn Hills, MI

San Antonio, TX

Saskatoon, Canada

Calgary, Canada

Sparks Location

Reno - Moana Lane Location

Vida Dermatology South

Rocklin, CA

Women´s Health Institute

Prague, Czech Republic

Grodzisk Mazowiecki, Poland

Dupnitsa, Bulgaria

Bluefin Biomedicine, Inc.

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.

This study is seeking participants who:

* are 18 years of age or more.
* Were confirmed to have AD at least 6 months ago.
* Are not having an effective treatment result from medicines that are applied on skin for AD.
* Are considered by their doctors to have moderate to severe AD.

In Stage 1 of the study, participants will receive either PF-07275315 or PF-07264660 or placebo. Stage 1 is complete. In Stage 2 of the study participants will receive either PF-07275315 or placebo. In Stage 3 of the study participants who have received anti-inflammatory proteins, will receive either PF-07275315 or placebo. In Stage 4 of the study participants will receive either PF-07264660 or placebo. A placebo does not have any medicine in it but looks just like the medicines being studied.

PF-07275315 or PF-07264660 or placebo will be given as multiple shots in the clinic over the course of each Stage.

The experiences of people receiving PF-07275315 or PF-07264660 will be compared to people who do not. This will help determine if PF-07275315 and PF-07264660 are safe and effective.

Participants in Stages 1, 2 and 4 will be involved in this study for up to 40 weeks (10 months). Participants in Stage 3 will be involved in this study for up to 52 weeks (13 months).

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Find clinical trials for Eczema in Orlando, FL

Related conditions:

Eczema trials near Orlando, FL, USA:

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis (COMPASS 2-AD)

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Find clinical trials for Eczema in .css-epvm6{white-space:nowrap;}Orlando, FL

Related conditions:

Eczema trials near Orlando, FL, USA:

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis (COMPASS 2-AD)

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Find clinical trials for Eczema in Orlando, FL